Management of Advanced Prostate Cancer in the Precision Oncology Era

Area of Science:

• Oncology
• Precision Medicine
• Radiopharmaceutical Therapy

Background:

• Prostate cancer (PC) is a leading cause of cancer death in men.
• Metastatic castration-resistant prostate cancer (mCRPC) remains incurable, necessitating novel therapeutic strategies.
• Recent advancements in systemic therapies and precision oncology offer new hope for patients with advanced PC.

Purpose of the Study:

• To review seminal clinical data supporting new precision oncology therapeutics for PC.
• To explore the limitations, utility, and potential of these novel treatments.
• To detail recent advances in biomarker-driven therapies and theranostics for PC.

Main Methods:

• Review of clinical data for precision oncology therapeutics in prostate cancer.
• Analysis of biomarker-driven therapies, including PD-1 inhibitors and PARP inhibitors.
• Evaluation of theranostic agents, such as PSMA-targeted radioligand therapies.

Main Results:

• Biomarker-driven therapies are bringing precision oncology closer to reality for all PC patients.
• Tumor-agnostic approval of pembrolizumab (PD-1 inhibitor) signifies a major step forward.
• PSMA-targeted theranostics are transforming PC diagnosis and treatment, with recent FDA approvals for mCRPC.

Conclusions:

• Precision-based oncology has significantly advanced the treatment landscape for prostate cancer.
• Theranostic agents and biomarker-driven therapies represent key innovations in managing advanced and metastatic PC.
• Continued research and application of these precision approaches hold promise for improving outcomes in PC.